Eur Urol 2021 Dec
Stereotactic Radiotherapy for Oligoprogression in Metastatic Renal Cell Cancer Patients Receiving Tyrosine Kinase Inhibitor Therapy: A Phase 2 Prospective Multicenter Study.
Related Questions
Data is still lacking regarding a possible synergistic effect with radiation and TKI. Would you be concerned that this would cause more side effects t...
New comment by Radiation Oncologist at Memorial Sloan Kettering Cancer Center ( February 10, 2025)
To this point, an important question to ask is about competing risks. If this is a man with favorable intermediate-risk prostate cancer and metastatic RCC, does active surveil...